Moderna and Merck report 42% reduction in death and recurrence with mRNA cancer vaccine

Moderna and Merck announced top-line results showing their mRNA cancer vaccine reduced death and recurrence rates by 42%. This update follows earlier reports indicating the trial's success, marking a significant advancement in cancer treatment research.

Originally published by arstechnica